+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Viral Vectors and Plasmid DNA Manufacturing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033- Product Image
Viral Vectors and Plasmid DNA Manufacturing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033- Product Image
New

Viral Vectors and Plasmid DNA Manufacturing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033

  • PDF Icon

    Report

  • 179 Pages
  • February 2024
  • Region: Global
  • Acute Market Reports
  • ID: 5830639
Description Jump to:
The global viral vectors and plasmid DNA manufacturing market witnessed substantial growth in recent years. The market was valued at US $6.32 billion in 2024, and it was expected to continue its upward trajectory during the forecast period by registering an expected CAGR of 22.21% during the forecast period of 2025 to 2033. Increasing investments in research and development, coupled with the rising demand for gene therapies, were significant drivers contributing to market expansion. Gene therapies have emerged as revolutionary treatment modalities with potential applications in various therapeutic areas. Key applications of viral vectors and plasmid DNA manufacturing included gene therapy, cell therapy, antisense & RNAi therapy, and vaccinology. These therapies were being explored to address a wide range of diseases, such as cancer, genetic disorders, infectious diseases, and rare diseases. Viral vectors are essential components for gene delivery in gene therapies. The market included various vector types, such as Adenovirus, Retrovirus, Adeno-Associated Virus (AAV), Lentivirus, Plasmids, and Others. Additionally, the manufacturing workflows were categorized into upstream and downstream manufacturing, encompassing vector amplification & expansion, vector recovery/harvesting, purification, and fill finish.

Increasing demand for gene therapies and personalized medicine

The increasing demand for gene therapies and personalized medicine is a key driver propelling the growth of the global viral vectors and plasmid DNA manufacturing market. Gene therapies offer the potential to treat genetic and acquired diseases at the genetic level, providing targeted and precise interventions tailored to individual patients. The rise in the prevalence of genetic disorders and chronic diseases has underscored the need for more effective and curative treatment options, fostering the adoption of gene therapies across various medical conditions. The approval of several gene therapies by regulatory agencies has further boosted the demand for personalized medicine. For instance, in 2024 the latest significant update regarding Kymriah (tisagenlecleucel), a CAR-T cell therapy developed by Novartis, is its approval by the U.S. Food and Drug Administration (FDA) for a new indication. The FDA approved a supplement to the Biologics License Application for Kymriah to update its labeling with new safety information concerning the risk of T cell malignancies following treatment with genetically modified autologous T cell immunotherapies. This includes a new boxed warning and other updates to the package insert's safety sections.

Combination Therapies 

The opportunity to explore combination therapies that utilize viral vectors and plasmid DNA in conjunction with other treatment modalities, such as immunotherapies or traditional pharmaceuticals, holds immense potential for enhancing treatment outcomes. Combining different therapeutic approaches can lead to synergistic effects, improved efficacy, and enhanced patient responses.

Complex regulatory approval processes for gene therapies

One of the significant restraints affecting the global viral vectors and plasmid DNA manufacturing market is the complex regulatory approval processes for gene therapies. While the regulatory landscape has evolved to support the development of innovative treatments, gene therapies present unique challenges that require rigorous evaluation to ensure patient safety and efficacy. The regulatory agencies' stringent requirements and the need for robust clinical data contribute to extended timelines and high costs for gaining approvals. According to a study published in Nature Reviews Drug Discovery, the average time for regulatory approval of gene therapies in the United States is around 17.3 months, compared to the average time of 12.1 months for non-gene therapy biologics. This reflects the additional scrutiny and evaluation gene therapies undergo during the approval process.

By Vector Type

AAV vectors dominated the gene therapy market in 2024, primarily due to their favorable safety profile, with low immunogenicity compared to other vectors like Adenovirus and Retrovirus, reducing the risk of immune responses. AAV's ability to mediate long-term gene expression is crucial for the sustained effectiveness of treatments, particularly for chronic and genetic disorders. Its versatility in infecting both dividing and non-dividing cells broadens its applicability across various diseases and tissues. The clinical success of AAV-based therapies, especially in treating conditions like spinal muscular atrophy and inherited retinal disorders, has bolstered its adoption in gene therapy development. Significant investments in R&D and several regulatory approvals in regions like the U.S. and Europe have reinforced confidence in AAV technologies. Moreover, advancements in manufacturing technologies have enhanced the scalability and cost-efficiency of AAV production, supporting its commercial expansion and market prominence.

By Application

In 2024, Vaccinology led the gene therapy market primarily due to the impact of the global COVID-19 pandemic, which underscored the essential role of vaccines in controlling infectious diseases. The urgent demand for COVID-19 vaccines spurred rapid development efforts, highlighting the efficiency of Vaccinology. Technological advancements in viral vectors and plasmid DNA have accelerated vaccine development, enabling responses to a wider array of infectious diseases. Significant government and private funding supported these rapid advancements, reinforcing the field’s prominence. Beyond COVID-19, gene-based vaccines are increasingly being explored for diseases like HIV, influenza, and Zika virus, expanding the scope of Vaccinology. The heightened focus on public health and preventive medicine has bolstered the appeal of gene-based vaccines, known for inducing effective and durable immune responses. Additionally, extensive collaboration among research entities, pharmaceutical firms, and governments during the pandemic has fueled progress in this area. Enhanced regulatory support for fast-tracking vaccine approvals during health crises has further promoted investment and research in Vaccinology, solidifying its leadership in the market.

By Region

North America is expected to register the highest CAGR during the forecast period of 2025 to 2033 followed by APAC. North America has a robust research and development ecosystem, with significant investments in biotechnology and gene therapy research. The presence of renowned research institutions, academic centers, and biopharmaceutical companies contributes to the region's innovation and advances in viral vectors and plasmid DNA manufacturing. The United States, in particular, has been at the forefront of regulatory support for gene therapies. Expedited review processes and accelerated approvals by the FDA have encouraged the development and commercialization of gene therapies in the region.

Market Competition to Intensify During the Forecast Period

The viral vectors and plasmid DNA manufacturing market is highly competitive, with several key players actively participating in the development and production of viral vectors and plasmid DNA for gene therapies and vaccines. These companies are focusing on strategic initiatives to strengthen their market presence and gain a competitive edge. One of the top players in the market is Lonza Group, a global contract development and manufacturing organization (CDMO). Lonza offers a wide range of services, including viral vector manufacturing, plasmid DNA production, and process development.Key strategies adopted by top players and others in the market include investing in research and development activities to enhance manufacturing processes, expanding production capacity to meet the growing demand, and establishing strategic partnerships and collaborations to access novel technologies and broaden their market reach. These companies are also focusing on ensuring regulatory compliance, quality assurance, and adherence to good manufacturing practices to meet the stringent requirements of the gene therapy and vaccine industry. Moreover, competition in the viral vectors and plasmid DNA manufacturing market is further intensified by emerging players and start-ups that are entering the market with innovative technologies and platforms. These players are leveraging advancements in biotechnology and genetic engineering to develop novel viral vectors and plasmid DNA manufacturing approaches.

Historical & Forecast Period

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Viral Vectors and Plasmid DNA Manufacturing market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users & consumption volume, price, and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Viral Vectors and Plasmid DNA Manufacturing market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

Vector Type

  • Adenovirus
  • Retrovirus
  • Adeno-Associated Virus (AAV)
  • Lentivirus
  • Plasmids
  • Others

Workflow

  • Upstream Manufacturing
  • Vector Amplification & Expansion
  • Vector Recovery/Harvesting
  • Downstream Manufacturing
  • Purification
  • Fill Finish

Application

  • Antisense & RNAi Therapy
  • Gene Therapy
  • Cell Therapy
  • Vaccinology
  • Research Applications

End-use

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

Disease

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others

Region Segment (2023 - 2033; US$ Million)

  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Viral Vectors and Plasmid DNA Manufacturing market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2033.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Viral Vectors and Plasmid DNA Manufacturing market?
  • Which is the largest regional market for Viral Vectors and Plasmid DNA Manufacturing market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Viral Vectors and Plasmid DNA Manufacturing market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Viral Vectors and Plasmid DNA Manufacturing market worldwide?

This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Viral Vectors and Plasmid DNA Manufacturing Market
2.2. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2024 (US$ Million)
2.3. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2024 (US$ Million)
2.4. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2024 (US$ Million)
2.5. Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2024 (US$ Million)
2.6. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2024 (US$ Million)
2.7. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Geography, 2024 (US$ Million)
2.8. Attractive Investment Proposition by Geography, 2024
3. Viral Vectors and Plasmid DNA Manufacturing Market: Competitive Analysis
3.1. Market Positioning of Key Viral Vectors and Plasmid DNA Manufacturing Market Vendors
3.2. Strategies Adopted by Viral Vectors and Plasmid DNA Manufacturing Market Vendors
3.3. Key Industry Strategies
4. Viral Vectors and Plasmid DNA Manufacturing Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Viral Vectors and Plasmid DNA Manufacturing Market Value, 2023 - 2033, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape
5. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2024 Versus 2033
5.3. Market Segmentation
5.3.1. Adenovirus
5.3.2. Retrovirus
5.3.3. Adeno-Associated Virus (AAV)
5.3.4. Lentivirus
5.3.5. Plasmids
5.3.6. Others
6. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2024 Versus 2033
6.3. Market Segmentation
6.3.1. Upstream Manufacturing
6.3.1.1. Vector Amplification & Expansion
6.3.1.2. Vector Recovery/Harvesting
6.3.2. Downstream Manufacturing
6.3.2.1. Purification
6.3.2.2. Fill Finish
7. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2024 Versus 2033
7.3. Market Segmentation
7.3.1. Antisense & RNAi Therapy
7.3.2. Gene Therapy
7.3.3. Cell Therapy
7.3.4. Vaccinology
7.3.5. Research Applications
8. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
8.1. Market Overview
8.2. Growth & Revenue Analysis: 2024 Versus 2033
8.3. Market Segmentation
8.3.1. Pharmaceutical and Biopharmaceutical Companies
8.3.2. Research Institutes
9. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
9.1. Market Overview
9.2. Growth & Revenue Analysis: 2024 Versus 2033
9.3. Market Segmentation
9.3.1. Cancer
9.3.2. Genetic Disorders
9.3.3. Infectious Diseases
9.3.4. Others
10. North America Viral Vectors and Plasmid DNA Manufacturing Market, 2023-2033, USD (Million)
10.1. Market Overview
10.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
10.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
10.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
10.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
10.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
10.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2023-2033, USD (Million)
10.7.1.North America
10.7.1.1. U.S.
10.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
10.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
10.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
10.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
10.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
10.7.1.2. Canada
10.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
10.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
10.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
10.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
10.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
10.7.1.3. Rest of North America
10.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
10.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
10.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
10.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
10.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
11. UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market, 2023-2033, USD (Million)
11.1. Market Overview
11.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
11.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
11.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
11.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
11.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
11.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2023-2033, USD (Million)
11.7.1.UK and European Union
11.7.1.1. UK
11.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
11.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
11.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
11.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
11.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
11.7.1.2. Germany
11.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
11.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
11.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
11.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
11.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
11.7.1.3. Spain
11.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
11.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
11.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
11.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
11.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
11.7.1.4. Italy
11.7.1.4.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
11.7.1.4.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
11.7.1.4.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
11.7.1.4.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
11.7.1.4.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
11.7.1.5. France
11.7.1.5.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
11.7.1.5.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
11.7.1.5.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
11.7.1.5.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
11.7.1.5.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
11.7.1.6. Rest of Europe
11.7.1.6.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
11.7.1.6.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
11.7.1.6.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
11.7.1.6.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
11.7.1.6.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
12. Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market, 2023-2033, USD (Million)
12.1. Market Overview
12.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
12.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
12.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
12.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
12.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
12.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2023-2033, USD (Million)
12.7.1.Asia Pacific
12.7.1.1. China
12.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
12.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
12.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
12.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
12.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
12.7.1.2. Japan
12.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
12.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
12.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
12.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
12.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
12.7.1.3. India
12.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
12.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
12.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
12.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
12.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
12.7.1.4. Australia
12.7.1.4.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
12.7.1.4.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
12.7.1.4.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
12.7.1.4.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
12.7.1.4.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
12.7.1.5. South Korea
12.7.1.5.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
12.7.1.5.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
12.7.1.5.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
12.7.1.5.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
12.7.1.5.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
12.7.1.6. Rest of Asia Pacific
12.7.1.6.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
12.7.1.6.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
12.7.1.6.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
12.7.1.6.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
12.7.1.6.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
13. Latin America Viral Vectors and Plasmid DNA Manufacturing Market, 2023-2033, USD (Million)
13.1. Market Overview
13.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
13.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
13.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
13.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
13.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
13.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2023-2033, USD (Million)
13.7.1.Latin America
13.7.1.1. Brazil
13.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
13.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
13.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
13.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
13.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
13.7.1.2. Mexico
13.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
13.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
13.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
13.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
13.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
13.7.1.3. Rest of Latin America
13.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
13.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
13.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
13.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
13.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
14. Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market, 2023-2033, USD (Million)
14.1. Market Overview
14.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
14.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
14.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
14.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
14.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
14.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2023-2033, USD (Million)
14.7.1.Middle East and Africa
14.7.1.1. GCC
14.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
14.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
14.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
14.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
14.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
14.7.1.2. Africa
14.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
14.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
14.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
14.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
14.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
14.7.1.3. Rest of Middle East and Africa
14.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2023-2033, USD (Million)
14.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2023-2033, USD (Million)
14.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2023-2033, USD (Million)
14.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2023-2033, USD (Million)
14.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2023-2033, USD (Million)
15. Company Profile
15.1. Lonza Group AG
15.1.1. Company Overview
15.1.2. Financial Performance
15.1.3. Product Portfolio
15.1.4. Strategic Initiatives
15.2. FUJIFILM Diosynth Biotechnologies
15.2.1. Company Overview
15.2.2. Financial Performance
15.2.3. Product Portfolio
15.2.4. Strategic Initiatives
15.3. Kaneka Eurogentec S.A.
15.3.1. Company Overview
15.3.2. Financial Performance
15.3.3. Product Portfolio
15.3.4. Strategic Initiatives
15.4. Oxford Biomedica plc
15.4.1. Company Overview
15.4.2. Financial Performance
15.4.3. Product Portfolio
15.4.4. Strategic Initiatives
15.5. Charles River
15.5.1. Company Overview
15.5.2. Financial Performance
15.5.3. Product Portfolio
15.5.4. Strategic Initiatives
15.6. Merck KGaA Group
15.6.1. Company Overview
15.6.2. Financial Performance
15.6.3. Product Portfolio
15.6.4. Strategic Initiatives
15.7. Thermo Fisher Scientific Inc.
15.7.1. Company Overview
15.7.2. Financial Performance
15.7.3. Product Portfolio
15.7.4. Strategic Initiatives
15.8. SIRION Biotech GmbH
15.8.1. Company Overview
15.8.2. Financial Performance
15.8.3. Product Portfolio
15.8.4. Strategic Initiatives
15.9. Catalent Inc.
15.9.1. Company Overview
15.9.2. Financial Performance
15.9.3. Product Portfolio
15.9.4. Strategic Initiatives
15.10. Wuxi Biologics
15.10.1. Company Overview
15.10.2. Financial Performance
15.10.3. Product Portfolio
15.10.4. Strategic Initiatives
15.11. Takara Bio Inc.
15.11.1. Company Overview
15.11.2. Financial Performance
15.11.3. Product Portfolio
15.11.4. Strategic Initiatives
15.12. Waisman Biomanufacturing
15.12.1. Company Overview
15.12.2. Financial Performance
15.12.3. Product Portfolio
15.12.4. Strategic Initiatives
15.13. Batavia Biosciences
15.13.1. Company Overview
15.13.2. Financial Performance
15.13.3. Product Portfolio
15.13.4. Strategic Initiatives
15.14. VGXI, Inc.
15.14.1. Company Overview
15.14.2. Financial Performance
15.14.3. Product Portfolio
15.14.4. Strategic Initiatives
List of Figures
FIG. 1 Global Viral Vectors and Plasmid DNA Manufacturing Market: Market Coverage
FIG. 2 Research Methodology and Data Sources
FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
FIG. 4 Global Viral Vectors and Plasmid DNA Manufacturing Market: Quality Assurance
FIG. 5 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2024
FIG. 6 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2024
FIG. 7 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2024
FIG. 8 Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2024
FIG. 9 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2024
FIG. 10 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Geography, 2024
FIG. 11 Market Geographical Opportunity Matrix - Global Viral Vectors and Plasmid DNA Manufacturing Market, 2024
FIG. 12 Market Positioning of Key Viral Vectors and Plasmid DNA Manufacturing Market Players, 2024
FIG. 13 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2024 Vs 2033, %
FIG. 14 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2024 Vs 2033, %
FIG. 15 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2024 Vs 2033, %
FIG. 16 Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2024 Vs 2033, %
FIG. 17 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2024 Vs 2033, %
List of Tables
TABLE 1 Global Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 2 Global Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 3 Global Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 4 Global Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 5 Global Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 6 Global Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 7 Global Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 8 North America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 9 North America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 10 North America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 11 North America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 12 North America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 13 North America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 14 North America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 15 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 16 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 17 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 18 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 19 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 20 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 21 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 22 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 23 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 24 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 25 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 26 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 27 Canada Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 28 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 29 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 30 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 31 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 32 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 33 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 34 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 35 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 36 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 37 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 38 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 39 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 40 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 41 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 42 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 43 UK Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 44 UK Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 45 UK Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 46 UK Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 47 UK Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 48 UK Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 49 UK Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 50 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 51 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 52 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 53 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 54 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 55 Germany Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 56 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 57 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 58 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 59 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 60 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 61 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 62 Spain Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 63 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 64 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 65 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 66 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 67 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 68 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 69 Italy Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 70 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 71 France Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 72 France Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 73 France Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 74 France Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 75 France Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 76 France Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 77 France Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 78 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 79 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 80 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 81 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 82 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 83 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 84 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 85 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 86 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 87 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 88 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 89 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 90 Asia Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 91 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 92 China Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 93 China Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 94 China Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 95 China Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 96 China Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 97 China Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 98 China Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 99 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 100 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 101 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 102 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 103 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 104 Japan Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 105 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 106 India Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 107 India Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 108 India Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 109 India Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 110 India Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 111 India Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 112 India Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 113 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 114 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 115 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 116 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 117 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 118 Australia Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 119 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 120 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 121 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 122 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 123 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 124 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 125 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 126 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 127 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 128 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 129 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 130 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 131 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 132 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 133 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 134 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 135 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 136 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 137 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 138 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 139 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 140 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 141 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 142 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 143 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 144 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 145 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 146 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 147 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 148 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 149 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 150 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 151 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 152 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 153 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 154 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 155 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 156 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 157 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 158 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 159 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 160 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 161 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 162 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 163 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 164 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 165 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 166 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 167 GCC Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 168 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 169 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 170 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 171 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 172 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 173 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 174 Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 175 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)
TABLE 176 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2023-2033, USD (Million)
TABLE 177 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2023-2033, USD (Million)
TABLE 178 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2023-2033, USD (Million)
TABLE 179 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2023-2033, USD (Million)
TABLE 180 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2023-2033, USD (Million)
TABLE 181 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2023-2033, USD (Million)
TABLE 182 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2023-2033, USD (Million)

Companies Mentioned

  • Lonza Group AG
  • FUJIFILM Diosynth Biotechnologies
  • Kaneka Eurogentec S.A.
  • Oxford Biomedica plc
  • Charles River
  • Merck KGaA Group
  • Thermo Fisher Scientific Inc.
  • SIRION Biotech GmbH
  • Catalent Inc.
  • Wuxi Biologics
  • Takara Bio Inc.
  • Waisman Biomanufacturing
  • Batavia Biosciences
  • VGXI, Inc.

Related Topics

Related Reports

Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type: Global Opportunity Analysis and Industry Forecast, 2024-2033 - Product Image

Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • Report
  • 280 Pages
  • Global
From
Viral Vector & Plasmid DNA Manufacturing Market by Type, Cell Line, Transfection, Indication, Workflow, Application, End User - Global Forecast 2025-2030 - Product Image

Viral Vector & Plasmid DNA Manufacturing Market by Type, Cell Line, Transfection, Indication, Workflow, Application, End User - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Viral Vector and Plasmid DNA: Technologies and Global Markets - Product Image

Viral Vector and Plasmid DNA: Technologies and Global Markets

  • Report
  • 128 Pages
  • Global
From
Adeno-Associated Viral Vectors Global Market Report 2024 - Product Image

Adeno-Associated Viral Vectors Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Viral Vector Manufacturing Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Viral Vector Manufacturing Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.